What AI says about Remix Therapeutics

Remix Therapeutics is a clinical-stage biotechnology company developing small molecule therapies that modulate RNA processing to address the underlying drivers of disease. Their proprietary REMaster platform designs small molecules to control RNA processing and modulate expression of disease-driving proteins, with their lead candidate REM 422 targeting the previously undruggable MYB transcription factor.